CompletedNCT00208819
Antipsychotic treatment alone or with divalproex for dementia-related agitation
About this title
Read the official source — NCT00208819Medication studyAges 65+United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 65 years.
- Listed locations
- AtlantaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 65 Years
- Official registry ID
- NCT00208819
- Official title
Show the full official title
Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Did this study involve medication?
Yes. The study involved medication, including risperidone, quetiapine, olanzapine and divalproex.
Who was this study for?
Listed age limits: from 65 years.
